AG0073-01-US Information Disclosure Statement For Divisional Appln.

certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV341079272US) in an envelope addressed to:

Mail Stop: Patent Application Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

on this 17th day of July 2003.

Nunus

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Steven Lee Bender et al.

Serial No.: Not Yet Assigned

Examiner: HABTE, KAHSAY

Group Art Unit: 1624

Filed: Herewith

For: AMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND

METHODS FOR THEIR USE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Mail Stop: Patent Applications Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form to Applicant.

Copies of the cited documents are not enclosed since they were previously cited by or submitted to the PTO in Application Serial No. 09/764,306, filed January 19, 2001 upon which the present application relies for priority benefit under 35 U.S.C. § 120.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified at 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

doseph F. Reidy Attorney For Applicants Registration No. 39,340

Date:

Agouron Pharmaceuticals, Inc./A Pfizer Company

Patent Department

10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-7320

Fax: (858) 678-8233

· 	FORM	PTC)49)		ATTY. DOCK	ET NC	A	PPLICATION N	10:
					0073-01-US TBA				
INFORMAT	ION DISC	CLOSURE	STATE	MENT	APPLICANT(
					S. Bender et a				
		•			FILING DAT		ĪG	ROUP	
					Herewith	•		514	
				U.S. F	PATENT DOCU	MENTS			
EXAMINER	7	DOCU	MENT	DATE	NAME	10	CLASS	SUB-CLASS	FILING DATE
INITIAL		NUME	BER]	
	AA1	5,621,0	082					 	
	AB1	6,020,3	336		1			<u> </u>	
	AC1	6,046,2	205						
	AD1	3,862,9			 				
	AE1	5,612,	360		 			 	
	AF1	5,733,9	920		 			 	
 -	AG1	4,826,9				 -	· · · · · · · ·	 	
	AH1	4,5003	40	~	 			 	
	AI1				 				
	AJ1				 			 	
	AK1				 			 	
				FOREIG	N PATENT DO	CUMENTS		<u> </u>	
EXAMINER		DOCU	MENT	DATE	COUNTRY		LASS	SUB-	TRANSLATION
INITIAL		NUME	BER			ļ	1	CLASS	
	AL1	WO 97	7/34876						□Yes □ No
	AM1	WO 97	7/03967						□Yes □ No
	AN1	WO 96	5/23783		 				□Yes
		<u> </u>							□ No
	AO1	EP 066	56 270					}	□Yes
	AP1	A2	7/2 5 4 1 5						□ No
	API	WO 9	7/16447						□Yes □ No
	AQ1	ED 0.7	31 385		- 				□Yes
	11.01	LI U	31 303					1	□ No
				ŀ		l		1	LJ 110
			THER (I	ncluding A	uthor, Title, Da	te Pertinent P	ages etc		
	AR	1						vth & Differentia	ation 8 3-10
		-	(1997)	1105, 7., 1 4	idua, 15.1 ., 1101111	omey 01, 141., O	on Grov	viii & Billotoitii	
· .	AS	1	Folkma	n, Nature I	Med., 1, 27-31 (1995)			
	AT	1	Strawn	et al., Cano	cer Research, 56	, 3540-3545 (1996)		
•									
	AU	1	Lin et a	l., J. Med.	Chem., 15 (6),	615-618, 1972	2		
	AV	1	Rosowe	kvetal T	. Med. Chem., V	701.31.763-76	58 1988		
		-	1030 W3	ky et al., s	· Mod. Onom., •		50, 1500		
		L							
EXAMINER					DAT	E CONSIDER	ŒD		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

	FORM :	P.)449			ATTV I	OCKET N	<u> </u>	T A 1	PPLICATION N	1 agc 2 01 11
	FURINI .	r			h		-ar			NO:
INFORMATI	ON DISC	LOSURE	STATE	MENT	APPLIC	3-01-US			BA	
IN ORGANIA	OI DIDC	LODOIG	DINIL	VILITI	ATTL	В	ender e	et	al.	
					FILING	DATE	-	G	ROUP	
					Here	with				
				U.S. 1	PATENT D	with OCUMENT	S			
EXAMINER INITIAL		DOCU NUMB	MENT BER	DATE	NAME		CLA	SS	SUB-CLASS	FILING DATE
	AA2									
	AB2									
	AC2									
	AD2									
	AE2					-				
	AF2				<u> </u>					
	AG2									
	AH2									<u> </u>
	AI2									ļ
	AJ2	 								
L	AK2			FOREIC	N. D. A TEXT	TDOCIDA	NITO			<u> </u>
EXAMINER		DOCT	MENT		COUNT	T DOCUME	CLAS	6 1	SUB-	TRANSLATION
INITIAL		NUME		DATE	COUN	IKI	CLAS	5	CLASS	TRANSLATION
	AL2	WO 99	9/21845							□Yes □ No
	AM2	WO 96	5/14843							□Yes
	1	""	3,110,15		-			1		□ No
	AN2	WO 99	9/06540	 	+					□Yes
		İ						Ì		□ No
	AO2	WO 97	7/42949					$\neg \uparrow$		□Yes
								İ		□ No
	AP2	WO 98	3/17662							□Yes
										□ No
		0				e, Date, Per			:.)	
			Millaue	r et al., Ca	incer Resea	rch, 56, 161	5-1620 (19	96)		
	AR	2								
	-		Vachiii	ot al Car	nor Decem	ch, 57, 3924	2028 (100	71		
		. 1	i osmji	cı aı., Car	icei Vesegi	ы, эт, ээ24	-2720 (133	"		
	AS	2								
		=								
<u> </u>	+		Moham	mad et al.	, EMBO Jo	urnal, 17, 58	396-5904 (1	998)	
•	AT	2				•	`	•		
EXAMINER						DATE CON	ISIDERED			· ·

EXAMINER: Initial if reference considered, whether or not citation is in a considered with FIPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

				T		·)		
	FORM I	PTO -49		1	OCKET NO:	م م	APPLICATION 1	NO.
					-01-US		TBA	
INFORMATIO	ON DISC	LOSURE STATE	MENT	APPLICA	ANT(S)	nder et	al	
				FILING		<u>.</u>	GROUP	
						1	GROOF	
·			HCI	Here	with OCUMENTS			
EXAMINER	Τ	DOGED (EXE			OCUMENTS		S SUB-CLASS	FILING DATE
INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	S SOB-CLASS	FILING DATE
	AA3							
	AB3							
	AC3		 					
	AD3	 						
	AE3	 	 	 		.		
	AF3		<u> </u>	 		- 	•	
	AG3		 	1				
	AH3		 	+				
 	AI3		 	 				
	AJ3		+					
	AK3		 	 				
			FOREIG	N PATEN	T DOCUMEN	ITS		_ \
EXAMINER	T	DOCUMENT	DATE	COUN		CLASS	SUB-	TRANSLATION
INITIAL		NUMBER					CLASS	
	AL3	WO 99/02162	 				·	□Yes
	1			-		}		□ No
	AM3	WO 99/43675	 					□Yes
	1			1		}		□ No
<u> </u>	AN3	WO 99/43676						□Yes
			ł			1		□ No
	AO3	WO 98/33798	1					□Yes
	1			- {			Ì	□ No
· · · · · · · · · · · · · · · · · · ·	AP3	WO 99/15500	1		· · · · · · · · · · · · · · · · · · ·	T		□Yes
			Ì					□ No
		OTHER	Including A	Author, Tit	le, Date, Pertir	ient Pages,	etc.)	·
		Maiso	npierre et a	I., Science,	277, 55-60 (1	997)	·····	
			•					
٠	AR	<u>3</u>		4				
i		-						
		Science	e, 274, 164	3-1677 (19	996)			
						,		
	AS	3						
		Hall e	t al., Adv. C	Cancer Res.	, 68, 67-108 (1996)		
	1							
	AT	3						
777.13.477.777		LL			DATE CON	ממממוי		
EXAMINER				1	DATE CONS	MEKED		
<u> </u>								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		\sim				-			-
	FORM	PTO 144	9	·	ATTY. DOCKE	TNO.	A	PPLICATION	10.
					0073-01-US		TI	ЗА	
INFORMAT	ION DISC	CLOSUR	E STATE	MENT	APPLICANT(S)				
					, ,	Bend	er et	al.	•
					FILING DATE		G	ROUP	
					Herewith				
					PATENT DOCUM	ENTS			· · · · · · · · · · · · · · · · · · ·
EXAMINER	•		UMENT	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
INITIAL	1	NUM	BER	<u> </u>	<u> </u>				
	AA4			ļ				1	
	AB4 AC4							ļ <u></u>	
	AD4			ļ				 	 -
	AE4			<u> </u>				 	
	AF4	+	· · · · ·		<u> </u>			 	
	AG4			 	 				
`	AH4			 	- 			 	
	AI4	- 						 	
·	AJ4			 	 				
	AK4	 -						 	
	1			FORFIG	N PATENT DOCU	IMENTS			<u> </u>
EXAMINER		DOCI	UMENT	DATE	COUNTRY		CLASS	SUB-	TRANSLATION
INITIAL		NUM						CLASS	
	AL4	WO 9	9/17769	†	-				□Yes
				·			:		□ No
	AM4	WO 9	9/24416						□Yes
									□ No
	AN4	WO 9	9/23077						□Yes
									□ No
	AO4	WO 9	4/14780						□Yes
									□ No
	AP4	WO 9	8/03487						□Yes
				<u> L. </u>	<u></u>				□ No
• • • • • • • • • • • • • • • • • • • •		(Author, Title, Date,			c.)	
			Kamb,	Frends in (Genetics, 11, 136-1	40 (1995))		•
	AR	4	ł						
		4							
			Kamb e	t al., Scien	ce, 264, 436-440 (1994)			
				,	, , , , , , , , , , , , , , , , , , , ,	,			
	AS	4							
				· 					
			Webster	r, Exp. Opi	in. Invest. Drugs, 7	, 865-887	(1998)		
	AT	4	·						
EVAMINED			<u> </u>		DATE (COMETE	70.00		
EXAMINER					DATE	CONSIDE	EKED		
									
EXAMINER: In	itial if ref	erence co	harahipm	whether	r not citation is in o	onformar	nce with N	IPEP 609 Drav	v line through
citation if not in	conforma	ince and t	not concid	ered Inch	ude copy of this for	rm with n	ext comm	unication to Ann	olicant.
	20111011110	and i	-01 001131U	orea. IIICI	ade copy of this to.	** 1511 11	commi		

				*	ATTY. DOCKE	1. /	A	PPLICATION N	iO,
FORM PTO 1449					0073-01-US TBA				
	FORM	P10 144	9		APPLICANT(S) Bender et al.				
INFORMATION	ON DISC	CLOSURI	ESTATE	MENT	FILING DATE	Dende			···
INFORMATION DISCLOSURE STATEMENT									
<u> </u>				U.S. I	Herewith PATENT DOCUM	TENTS			
EXAMINER	Τ	DOCU	JMENT	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
INITIAL		NUM	BER						
	AA5				·				
	AB5							<u> </u>	
 	AC5 AD5			ļ		<u> </u>			
	AE5				 				
	AF5								
	AG5				 	 -			<u> </u>
	AH5	_		ļ	1				
	AI5			 	+				
	AJ5				<u> </u>				
	AK5								
				FOREIG	N PATENT DOC	UMENTS			
EXAMINER			JMENT	DATE	COUNTRY	C	LASS	SUB-	TRANSLATION
INITIAL	1.7.5	NUM		<u> </u>				CLASS	
	AL5	WO 9	8/38168						□Yes □ No
	AM5	WO 9	9/43663						□Yes □ No
	AN5		030563						□Yes
	AO5	A2	0/50050		<u> </u>				□ No
	AUS	WU9	9/59959						□Yes □ No
	AP5	WO 9	6/30015						□Yes □ No
	AQ5	EP 07	67172	 	 			<u> </u>	□Yes
	AQS	LI 07	0/1/2	İ					□ No
,				1					110
			THER (I	ncluding A	uthor, Title, Date	, Pertinent F	Pages, etc	;.)	
			Stover,	et al., Curr	. Opin. Drug Disc	Dev. 2, 27	4-285 (1	999)	
	AR	5							
						•			
	<u> </u>		Gray et	al., Curr. I	Med. Chem., 6, 85	9-875 (1999	9)		
		[•	, ,	`			
	AS	5		•					
· · · · · · · · · · · · · · · · · · ·	 	ļ			. 1	10 (0000)			
			Sielecki	, et al., J. I	Med. Chem., 43, 1	-18 (2000)			•
	AT	<u>5</u>							
	-	-	1.						
EXAMINER		•	-	····	DATE	CONSIDE	RED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOS E CITATION (Use several sheets if sary)

Applicant(s) S. Bender et al	-
Filing Date	Group Art Unit
Herewith	1614

		Herewith Aut.
*EXAMINER		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
INITIAL		Crews, et al., Curr. Opin. Chem Biol., 4, 47-53 (2000)
	AA6	
		Buolamwini, Curr. Pharm. Des., 6, 379-392 (2000)
	AB6	
2	}	
·		Rosania, et al., Exp. Opin. Ther. Pat., 10, 215-230 (2000)
	AC6	
·	+	O'Connor, Cancer Surveys, 29, 151-182 (1997)
		(2007)
	AD6	
		Nurse, Cell, 91, 865-867 (1997)
	AE6	
		Hartwell et al. Science, 266, 1821-1828 (1994)
	AF6	
		Hartwell et al., Science, 246, 629-634 (1989)
	AG6	
		D 4 1 5 1 20 400 4000
		Bunz et al., Science, 28, 1497-1501 (1998)
	AH6	
		Winters et al., Oncogene, 17, 673-684 (1998)
	AI6	
	7,720	
		Thompson, Oncogene, 15, 3025-3035 (1997)
	AJ6	
		Dans et al. Science 200 1501 1505 (1900)
		Peng et al. Science, 277, 1501-1505 (1997)
	AK6	
l		
	Ī	Sanchez et al., Science, 277, 1497-1501
	AL6	
	,,,,,,	
EXAMINER		DATE CONSIDERED
LAGAIN VOIC		
1		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance a not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLO

Applicant(s) S. Bender et al.	•
Filing Date	Group Art Unit
Herewith ;	1614

*EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title	, Date, Pertinent Pages, Etc.)
W-414764		Weinert, Science, 277, 1450-1451 (1997)	
	AA7		
		Walworth et al., Nataure, 363, 368-371 (1993)	
	AB7		
	 	Al-Khodairy et al., Molec. Biol. Cell, 5, 147-160 (199	04)
		Al-Modali y et al., Molec. Biol. Cell, 5, 147-100 (17)	(4.5)
	AC7		
		Zeng, et al., Nature, 395, 507-510 (1998)	
	AD7		
		Matsuoka, Science, 282, 1893-1897 (1998)	
	AE7		
	<u> </u>	P. I. O. O. C. C. C. C. C. C. C. C. C. C. C. C. C.	
i i		Bolen, Oncogene, 8, 2025-2031 (1993)	
	AF7		
	 	McMahon et al., Current Opinion in Drug Discover	y & Development, 1, 131-146 (1998)
	AG7		
	AG		
		Strawn et al., Exp. Opin. Invest. Drugs, 7, 553-573 ((1998)
	AH7		
	-		2.4600
market in the second		Adams et al., Curr. Opin. Drug Disc. Dev., 2, 96-10	9 (1999)
	AI7		
·		Toledo et al., Curr. Med. Chem., 6, 775-805 (1999)	
	AJ7		
		Garcia-Echeverria, et al., Med. Res. Rev., 20, 28-57	(2000)
	AK7		
		Bertolini et al., J. Med. Chem., 40, 2011-2016 (1997	
	AL7		
THE AMERICAN			DATE CONCIDENCE
EXAMINER			DATE CONSIDERED
l			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance.a not considered. Include copy of this form with next communication to applicant.

CITATION INFORMATION DISCLOS

(Use several sheets if nec.

Applicant(s) S. Bender et al. Filing Date Group Art Unit Herewith 1614

*EXAMINER		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
INITIAL		Shan, et al., J. Pharm. Sci., 86 (7), 765-767
	AA8	
		Bagshawe, Drug Dev. Res., 34, 220-230 (1995)
	AB8	
		Bodor, Advances in Drug Res., 13, 224-331 (1984)
	1.00	
	AC8	
		Bundgaard, Design of Prodrugs (Elsevier Press 1985)
	AD8	
	ADO	
		Larsen, Design and Application of Prodrugs, drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991)
	AE8	(Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991)
	ALG	
		Lee et al., Biochem, 23, 4255 (1984)
	AF8	
	Aro	
		Parast C. et al., BioChemistry, 34, 16788-16801 (1998)
	AG8	
	7.00	
		Jeffrey et al., Nature, 376, 313-320 (1995)
	AH8	
		Still et al., J. Org. Chem., 43, 2923 (1978)
	AI8	
		J. Am. Chem. Soc. 120, 9722-23 (1998)
	AJ8	
·		
		Forbes, et al., J. Med. Chem., 38, 2525 (1995)
	AK8	
<u> </u>		J. Med. Chem., 40, 2866-2875 (1997)
	AL8	
EXAMINER		DATE CONSIDERED
<u> </u>		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOS (Use several sheets if nec. Iny)

Applicant(s) S. Bender et al.	-
Filing Date	Group Art Unit
Herewith:	1614

Trova, M.P. et al.,	CUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) J. Med. Chem., 36, 580-590 (1993) , Mol. Cell, Biol., 16, 977-989 (1996) J. Mol. Biol., 230, 1317-1319 (1993)
Trova, M.P. et al., AA9 Mohammadi et al.	, Mol. Cell, Biol., 16, 977-989 (1996)
Mohammadi et al.	
Mohammadi et al.	
AB9	J. Mol. Biol., 230, 1317-1319 (1993)
	J. Mol. Biol., 230, 1317-1319 (1993)
	J. Mol. Biol., 230, 1317-1319 (1993)
Rosenblatt et al., J	
AC9	
Schang et al. I. V	irol. 74, 2107-2120 (2000)
- Straing et ali, or	101. 74, 2107-2120 (2000)
AD9	
Braun-Dullaeus et	al., Circulation, 98, 82-89 (1998)
AE9	
Taniguchi et al., N	ature Med., 5, 760-767 (1999)
AF9	
Ann. Rev. Cell De	v. Biol., Vol. 13, pp. 261-291 (1997)
AG9	
Lukas et al., Genes	s and Dev., Vol. 11, pp. 1479-1492 (1997)
АН9	
Harner Cancer Si	ırv., Vol. 29, pp. 91-107 (1997)
	117, 100 22, pp. 21-107 (1227)
A19	
DelSal et al., Critic	cal Rev. Oncogenesis, Vol. 71, pp. 127-142 (1996)
AJ9	
Nobori et al., Natu	re, Vol. 368, pp. 753-775 (1994)
AK9	
Loda et al., Nature	e Medicine, Vol. 3 (1997), pp. 231-234
AL9	
<u> </u>	
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLO. CITATION

(Use several sheets if ne.

Applicant(s)
S. Bender et al.

Filing Date

Herewith

1614

*EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Sherr, et al., Genes Dev., Vol. 13 (1999), pp. 1501-1512				
	ļ	,			
	AA10				
·	<u> </u>				
		Bandara, et al., Nature Biotechnology, Vol. 15 (1997	7), pp. 896-901		
	1				
	AB10				
	ļ				
	1	Chen, et al., Proceedings of the National Academy	of Science, USA, Vol. 96 (1999) pp. 4325-4329		
	1.010				
	AC10		•		
	} -		1000		
	1	Cohen, et al., Proc. Natl. Acad. Sci. U.S.A., Vol. 95 ((1998), pp. 14272-14277		
	AD10		•		
	1				
		Sedlacek et al., Int. J. Oncol., Vol. 9 (1996), pp. 114	2 1160		
		Sediacek et al., 11t. J. Oncol., Vol. 9 (1996), pp. 114.	3-1106		
	AE10		·		
	1				
	 	Schow et al., Bioorg. Med. Chem. Lett., Vol. 7 (1997)	7), pp. 2697-2702		
		(22)	, n = [
	AF10				
		Grant et al., Proc. Amer. Assoc. Cancer Res., Vol. 3	99 (1998), Abst. 1207		
	AG10				
	 				
	}	Legravend et al., Bioorg. Med. Chem. Lett., Vol. 8	(1998), pp. 793-798		
	AH10				
	 	Gray et al., Science, Vol. 281 (1998), pp. 533-538			
		Gray et al., Science, 701. 201 (1990), pp. 333-330			
	AI10				
	 	Chang, et al., Chemistry & Biology, Vol. 6 (1999),	эр. 361-375		
,					
	AJ10				
·					
		Ruetz et al., Proc. Amer. Assoc. Cancer Res., Vol. 3	9 (1998), Abst. 3794		
	1	,			
	AK10				
	<u> </u>				
·		Meyer et al., Proc. Amer. Assoc. Cancer Res., Vol.	39 (1998), Abst. 3794		
	AL10				
	ALIU				
	<u> </u>				
EXAMINER		•	DATE CONSIDERED		
			· ·		
L			<u></u>		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSE CITATION (Use several sheets if nice sary)

Applicant(s) S. Bender et al.	· •	
Filing Date	Group Art Unit	
Herewith	1614	

*EXAMINER	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
INITIAL	Owa, et al., J. Med. Chem., Vol. 42 (1999), pp. 3789-3799		
	AA11		
·····		Luzzio, et all, Proc. Amer. Assoc. Cancer Res., Vol. (1999), Abst. 4102	
	AB11		
		Schultz, et al., J. Med. Chem. Vol. (1999), pp. 2909-2919	
	AC11		
		Seitz, et al., 218th ACS Natl. Mtg. (Aug. 22-26, 1999, New Orleans), Abst MEDI 316	
	AD11		
	AE11	International Search Report from the European Patent Office for PCT Patent Application No. PCT/US01/01723, issued I the EPO on June 12, 2001.	
•			
,			
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.